Efectos del tratamiento con anti-TNF-a, infliximab, sobre la resistencia insulínica, adipocinas (visfatina, leptina, adiponectina, resistina y apelina) y angiopoyetina-2 en pacientes con espondilitis anquilosante

Abstract

Ankylosing Spondylitis (AS) is a chronic inflammatory disease that affects the spine causing sacroiliitis. These patients have accelerated atherogenesis and insulin resistance, which promotes endothelial dysfunction and increased cardiovascular risk. We have documented that the infusion of anti-TNF- a infliximab, in nondiabetic patients with AS improves insulin sensitivity and decreases serum angiopoietin-2 (endothelial activation marker involved in angiogenesis). It is known that systemic inflammation increases some serum adipokines and reduces some others, with en adverse effect on cardiovascular risk. In our study a correlation between the level of disease activity or systemic inflammation and serum levels of leptin, visfatin adiponectin, apelin, and resistin was not observed. Vistafin concentrations correlated with insulin resistance and adiponectin ones did so with insulin sensitivity. Apelin concentrations were not modified by the treatment.